Open access is a fantastic opportunity to make science accessible to all. Find out how to get all of the benefits without fearing the predators in our new podcast!
[podbean resource=”episode=pvrzv-9c6f45″ type=”audio-rectangle” height=”100″ skin=”1″ btn-skin=”107″ auto=”0″ download=”1″]
In this first instalment of the Open Pharma podcast, we look at the benefits of open access and how best to avoid predatory publishers. We speak with Chris Winchester, CEO of Oxford PharmaGenesis and co-founder of Open Pharma, about his passion for open access and his concerns about the potential impact of predatory publishing on the dissemination of medical research. Mary Yianni, Publisher at Taylor and Francis, then gives her insights into how to spot a predatory publisher.
Predatory publishing has been in the spotlight recently, following an investigation by The Guardian newspaper and German news corporation NDR into the vast number of research articles from respected institutions that have been published in bogus journals. There are people surrounding predatory publishing who fear that too much publicity will undermine faith in open access publishing. We want to bridge this gap by addressing both the benefits of open access, and how to avoid predatory publishers. This podcast provides a tool for researchers to pursue open access targets safely.
To access the podcast, use the player above to listen online or download and listen on the go!
We invite you to share this resource with any friends or colleagues involved in research to help us to reach a respected open future for scientific publishing.
About our speakers
Chris Winchester is the CEO of Oxford PharmaGenesis and co-founder of Open Pharma. Chris has worked in the field of HealthScience communications for over 15 years, and is passionate about putting patients at the heart of medical research and communications.
Mary Yianni is a publisher at Taylor & Francis, a publishing house with over 150 years of experience, and boasting an impressive roster of over 2000 academic journals. Mary specialises in medical journals, and developing new strategies for delivering sustainable open access.